---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031145"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T08:14:38.449862+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q3 net loss widens to $8.4M; Phase 2 COVID vaccine enrollment completed

## Summary
- Net loss $8.4M ($0.32/share) vs $3.97M ($0.17/share) in Q3 2022; cash $12.7M at Sep 30 vs $27.6M at Dec 31.
- R&D expenses rose to $6.9M from $2.7M, driven by clinical trial costs for GEO-CM04S1 and Gedeptin.
- Completed enrollment in Phase 2 trial of GEO-CM04S1 as a booster; initial data readout expected soon.
- Signed multi-product license with ProBioGen for AGE1.CR.pIX suspension cell line to enhance MVA vaccine manufacturing.
- Received U.S. patent allowances for Ebola, Marburg, Malaria, and HIV vaccines.

## SEC filing metadata
- accession: 0001437749-23-031145
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774923031145/0001437749-23-031145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774923031145/govx20231108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031145
- JSON: https://secwatch.observer/filing/0001437749-23-031145.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031145.txt

## Key facts
- Earnings Releases
  GeoVax Labs, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 8, 2023, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774923031145/0001437749-23-031145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.